Allergies, Gene Expression and Licensing - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Allergies

Gene Expression

Licensing

Tezepelumab granted Priority Review by U.S. FDA

The Pharma Data

JULY 8, 2021

Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for tezepelumab in the treatment of asthma. Ann Allergy Asthma Immunol. World Allergy Organization (WAO). EMJ Allergy Immunol. J Allergy Clin Immunol. Amgen (NASDAQ:AMGN) announced that the U.S.

Allergies

Allergies Trials In-Vivo Medicine

Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma

The Pharma Data

NOVEMBER 9, 2020

Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. 10 World Allergy Organization (WAO). EMJ Allergy Immunol. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol. 11 Busse WW.

Trials

Trials Production Sales Manufacturing

Tezepelumab granted Priority Review by U.S. FDA

Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma

Stay Connected